Clinical trials: Overweight, Obesity
Obesity
A Prospective, Multi-center, Single-arm Study of the Stomach, Intestinal and Pylorus Sparing (SIPS) Procedure
This study is a prospective, multi-center, single-arm study evaluating the SIPS procedure. Subjects who meet the eligibility criteria will be considered for study participation and will be followed through 12 months.
- Trial name
- NCT02275208
- Testing
- SIPS the stomach, intestinal, pylorus, sparing procedure
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Medtronic - MITG
Prader-Willi Syndrome
A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)
Open label, parallel-group, single site, 5 treatment-period study with 4 dose levels of DCCR, 1 of which is administered both with and without food.
- Trial name
- NCT02893618
- Testing
- Diazoxide choline controlled-release tablet
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Essentialis, Inc.
Overweight, Obese
The Study of [14C] GZR18
This trial is a Single-center, non-randomized, open-label, single-dose Mass Balance Study. The study period of each subject consists of a screening period (D-21 to D-2), a baseline period (D-2 to D-1), a dosing and routine…
- Conditions
- Overweight, Obese, Obesity
- Trial name
- NCT07119450
- Testing
- GZR18 injection、[14C]GZR18 injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Overweight or Obesity, Diabetes
A Study of SYH2069 Injection in Healthy Participants
To evaluate the safety and tolerability of single and multiple doses of SYH2069 Injection in healthy participants.
- Trial name
- NCT07736391
- Testing
- SYH2069 Injection
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Obesity
A Study to Test Different Doses of BI 456906 in Patients With Obesity
Main objective is to investigate the tolerability of different titration schemes of BI 456906 in otherwise healthy patients with obesity/overweight, and to determine a titration scheme for future studies.
- Trial name
- NCT03591718
- Testing
- BI 456906
- Where
- 2 sites in Germany
- Volunteers
- 131 people
- Sponsor
- Boehringer Ingelheim
Obesity
A Phase 1b Study to Evaluate the Safety of XEN-101
This Phase 1b study will evaluate the effects of XEN-101 in subjects with obesity
- Trial name
- NCT06417697
- Testing
- XEN-101
- Where
- Australia
- Volunteers
- 33 people
- Sponsor
- Xeno Biosciences
Type 2 Diabetes, Overweight and Obesity
A Phase I Study of GZR18 Injection in Healthy Subjects
This trial is conducted in China. The aim of the trial is to evaluate the safety and tolerability of GZR18 injection in healthy subjects following single dose and once-weekly dose for 2 consecutive weeks until reaching the target…
- Trial name
- NCT06548997
- Testing
- GZR18
- Where
- China
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Obese Adults
Evaluation of the Axomove Therapy Medical Device to Facilitate Adapted Physical Activity for Patients With Obesity
Background: Obesity affects 18.1% of adults in France and leads to numerous chronic complications as well as functional limitations (fatigability, dyspnea).
- Trial name
- ON-TRAC (NCT07903025)
- Testing
- Axomove Therapy, Standard multidisciplinary medical care
- Where
- 8 sites in France
- Volunteers
- 184 people
- Sponsor
- Axomove
Overweight, Obese
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese
This trial is being done to look at the safety and effect of combining cagrilintide and NNC0480-0389 in people living with overweight and obesity compared to taking cagrilintide alone.
- Trial name
- NCT07411560
- Testing
- Glucose-dependent Insulinotropic Polypeptide (GIP), Cagrilintide
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Novo Nordisk A/S
Obesity, Type 2 Diabetes
Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions DI Biofragmentable Magnetic Anastomosis System in Mexico
The purpose of this clinical research study is to evaluate the feasibility / performance, safety and initial efficacy of the GT Metabolic Solutions DI Biofragmentable Magnetic Anastomosis System (MAGNET System, DI…
- Trial name
- NCT07085741
- Testing
- MAGNET System, DI Biofragmentable
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- GT Metabolic Solutions, Inc.
Obesity, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM)
- Trial name
- NCT06305351
- Testing
- K-757 and K-833 QD, K-757 and K-833 BID
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- TriGemX Bio, Inc.
Obesity
A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity
The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as an oral tablet to Japanese participants.
- Trial name
- NCT06049329
- Testing
- NNC0487-0111
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study: To evaluate the efficacy of different dose levels of CX11 tablets in body weight reduction as compared to placebo.
- Trial name
- NCT07011797
- Testing
- CX11
- Where
- 17 sites in United States
- Volunteers
- 250 people
- Sponsor
- Corxel Pharmaceuticals
Morbid Obesity
European Union (EU) Post-Market Study on Easyband®
The purpose of this study is to collect additional safety, performance and effectiveness data of the Easyband gastric band medical device in the treatment of morbid obesity in 4 European countries where the device is a CE marked…
- Trial name
- NCT00948246
- Testing
- Easyband®
- Where
- 4 sites in Belgium, Italy and 2 more
- Volunteers
- 112 people
- Sponsor
- Allergan Medical
Overweight , Obesity
Study of UBT37034 Injection
This is a study of UBT37034 for injection in participants who have obesity or are overweight. The main purpose is to learn more about the safety, tolerability, drug concentration, drug action and immune response of repeated…
- Trial name
- NCT07873645
- Testing
- UBT37034
- Volunteers
- 40 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Sarcopenia, Obesity and Obesity-related Medical Conditions
INTERMEDIATE-SIZE PATIENT POPULATIONS EXPANDED ACCESS TO TREATMENT FOR SARCOPENIC OBESITY
The expanded access is designed for patients requesting the treatment, and whose medical condition may benefit from treatment, but are unable to participate in any other IMM01-STEM clinical trial in their physician's opinion for…
- Trial name
- STEM-META-EAP (NCT06784297)
- Testing
- IMM01-STEM
- Sponsor
- Immunis, Inc.
Obesity
INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records
The study is investigating the use of Saxenda (liragltuide 3.0 milligrams (mg) once daily) for weight management. The primary objective is to investigate the change in body weight after initiation and use of Saxenda ® according…
- Trial name
- INSPIRE Turkey (NCT05438186)
- Testing
- Liraglutide
- Where
- Turkey (Türkiye)
- Sponsor
- Novo Nordisk A/S
Obesity
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
- Trial name
- TRIUMPH-5 (NCT06662383)
- Testing
- Retatrutide, Tirzepatide
- Where
- 65 sites in United States, Argentina and 3 more
- Volunteers
- 800 people
- Sponsor
- Eli Lilly and Company
Obesity
Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women
This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on otherwise healthy participants with obesity.
- Trial name
- NCT06970405
- Testing
- Garetosmab
- Sponsor
- Regeneron Pharmaceuticals
Overweight, Obesity
A Study of LY3437943 in Chinese Participants With Obesity Or Overweight
The main purpose of this study is to learn about the safety and tolerability of LY3437943 when given to Chinese participants with overweight body mass index (BMI) or obesity.
- Trial name
- NCT05548231
- Testing
- LY3437943
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.